IRWD

Ironwood Pharmaceuticals Inc

3.62

Oct 29 • 3:59 PM ET +0.01 (0.28%)

3.58

Aftermarket • 7:30 PM ET -0.04 (-1.10%)

Healthcare Drug Manufacturers - Specialty & Generic USA Small NASD

Peers: ARDX BHC COLL TAK PHAT SUPN RDHL VNDA JAGX ABBV

| Held by: VTI IWM XBI VXF IWO CALF IBB DFAS FESM VTWO

Scroll to Statements

Index	RUT
Market Cap	598.17M
Enterprise Value	915.91M
Income	129.87M
Sales	389.32M
Book/sh	-0.98
Cash/sh	0.48
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	100
IPO	Feb 03, 2010

P/E	4.72
Forward P/E	2.75
PEG	0.02
P/S	1.54
P/B	-
P/C	7.56
P/FCF	3.22
EV/EBITDA	3.85
EV/Sales	2.35
Quick Ratio	6.06
Current Ratio	6.06
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	0.77
EPS next Y	1.32
EPS next Q	0.32
EPS this Y	715.56%
EPS next Y	7.63%
EPS next 5Y	112.04%
EPS past 3/5Y	-46.07% -25.92%
Sales past 3/5Y	-10.32% -5.33%
EPS Y/Y TTM	1922.25%
Sales Y/Y TTM	26.19%
EPS Q/Q	123.29%
Sales Q/Q	32.62%
Earnings	Nov 05 BMO
EPS/Sales Surpr.	-3.13% -1.57%

Insider Own	3.71%
Insider Trans	-2.38%
Inst Own	98.52%
Inst Trans	1.65%
ROA	41.35%
ROE	-
ROIC	56.04%
Gross Margin	99.53%
Oper. Margin	60.64%
Profit Margin	33.36%
SMA20	-0.26%
SMA50	-8.81%
SMA200	-9.29%
Trades

Shs Outstand	165.24M
Shs Float	159.10M
Short Float	9.99%
Short Ratio	8.01
Short Interest	15.89M
52W High	5.78 -37.37%
52W Low	1.47 146.17%
Volatility	3.62% 4.79%
ATR (14)	0.17
RSI (14)	44.95
Beta	0.24
Rel Volume	0.69
Avg Volume	1.98M
Volume	1,367,784

Perf Week	1.40%
Perf Month	-8.82%
Perf Quarter	-14.42%
Perf Half Y	-12.24%
Perf YTD	7.42%
Perf Year	139.74%
Perf 3Y	-58.82%
Perf 5Y	-71.65%
Perf 10Y	-67.21%
Recom	2.00
Target Price	6.10
Prev Close	3.61
Price	3.62
Change %	0.28%

Consensus

Buy

Avg. Price Target

$6.10

Implied Upside

+68.5%

Analysts13incl. previous ratings

Rating Distribution5 Buy · 8 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jan 05, 2026	Upgrade	CCitizens JMP	Mkt Perform → Mkt Outperform	$8	+121.0%
Apr 15, 2025	Downgrade	WWells Fargo	Overweight → Equal Weight
Apr 15, 2025	Downgrade	JJefferies	Buy → Hold
Apr 14, 2025	Downgrade	CCitizens JMP	Mkt Outperform → Mkt Perform
Sep 09, 2024	Initiated	LLeerink Partners	Market Perform	$5	+38.1%
Aug 08, 2024	Downgrade	CCapitalOne	Overweight → Equal Weight	$12 → $4	+10.5%
Jan 17, 2024	Initiated	CCraig Hallum	Buy	$21	+480.1%
Dec 14, 2023	Initiated	WWells Fargo	Overweight	$20	+452.5%
Nov 09, 2023	Initiated	JJefferies	Buy	$21	+480.1%
Sep 28, 2023	Initiated	JJMP Securities	Mkt Outperform	$22	+507.7%
Sep 02, 2022	Initiated	CCapitalOne	Overweight	$15	+314.4%
Apr 22, 2022	Initiated	PPiper Sandler	Overweight	$16	+342.0%
Sep 30, 2020	Downgrade	WWells Fargo	Overweight → Equal Weight	$14 → $9	+148.6%
Jun 17, 2020	Initiated	NNorthland Capital	Outperform	$14	+286.7%
Jul 10, 2019	Resumed	CCredit Suisse	Neutral
Mar 27, 2019	Upgrade	MMorgan Stanley	Underweight → Equal-Weight
Feb 25, 2019	Upgrade	HH.C. Wainwright	Sell → Neutral	$14	+286.7%
Jan 24, 2019	Upgrade	JJP Morgan	Underweight → Neutral
Nov 07, 2018	Downgrade	JJP Morgan	Neutral → Underweight
Nov 07, 2018	Downgrade	CCredit Suisse	Outperform → Neutral

Oct-28-26 09:51PM	Ironwood's Raised Linzess Outlook Faces A Proof Test As Shares Slide Below Key Support (Earnings Whispers)
04:05PM	Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call (Business Wire)
Oct-16-26 07:30AM	Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer (Business Wire) -7.16%
Sep-03-26 04:05PM	Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference (Business Wire)
Aug-06-26 07:16PM	Ironwood Pharmaceuticals Inc (IRWD) (Q2 2026) Earnings Call Highlights: Strong LINZESS Growth ... (GuruFocus.com)
07:21AM	Loading…
07:21AM	Ironwood: Q2 Earnings Snapshot (Associated Press)
07:05AM	Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results (Business Wire)
Jul-30-26 04:05PM	Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call (Business Wire) +13.40%
Jul-14-26 07:30AM	Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients (Business Wire) -5.46%
May-28-26 04:05PM	Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-27-26 10:00AM	FDA Approves Use of LINZESS (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC) (Business Wire)
May-07-26 07:18AM	Ironwood: Q1 Earnings Snapshot (Associated Press) -13.66%
07:05AM	Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance (Business Wire)
May-04-26 07:05AM	Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS) (Business Wire)
Apr-30-26 04:05PM	Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call (Business Wire) +7.64%
07:05AM	Loading…
Apr-23-26 07:05AM	Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week 2026 (Business Wire) -9.33%
Mar-06-26 08:21AM	Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4? (Zacks)
Mar-04-26 04:05PM	Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference (Business Wire)
Feb-26-26 10:40AM	IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks (Zacks) +8.93%
Feb-25-26 04:03PM	Ironwood Pharmaceuticals Inc (IRWD) Q4 2025 Earnings Call Highlights: Strong LINZESS Sales and ... (GuruFocus.com) -11.35%
03:29PM	Ironwood Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
12:15PM	Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:28AM	Ironwood: Q4 Earnings Snapshot (Associated Press Finance)
07:05AM	Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook (Business Wire)
Feb-23-26 09:07AM	What's in Store for These 5 Medical Companies This Earnings Season? (Zacks) -5.30%
Feb-20-26 10:57AM	Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now? (Zacks) -14.10%
Feb-18-26 04:21PM	Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call (Business Wire)
Feb-13-26 01:11PM	Waters Q4 Earnings Surpass Estimates, Revenues Increase Y/Y (Zacks)
Feb-12-26 10:35AM	IRWD Rises 307% in 6 Months: Is This an Indication to Buy the Stock? (Zacks)
Feb-08-26 08:28AM	3 Stocks Trading Near $5 With Massive Earnings Upside (MarketBeat)
08:48AM	Loading…
Feb-05-26 08:48AM	Does Ironwood's Bullish 2026 View Signal Greater Linzess Adoption? (Zacks)
Feb-04-26 09:06AM	Craig-Hallum Bullish on Ironwood Pharmaceuticals (IRWD), Keeps Buy Rating (Insider Monkey) -6.37%
Jan-26-26 02:11AM	Zacks.com featured highlights include IPG Photonics, Ironwood and Science Applications (Zacks)
Jan-23-26 10:33AM	4 Stocks Trading Near 52-Week High With More Upside Potential (Zacks)
Jan-08-26 09:36AM	Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics (Zacks)
Jan-07-26 03:25PM	Ironwood Pharmaceuticals' 2026 Guidance Shock Sparks a Major Re-Rating (MarketBeat) -5.12%
08:45AM	5 Small Drug Stocks to Buy as Industry Recovery Picks Up (Zacks)
Jan-05-26 10:28AM	Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026 (Zacks) +7.49%
Jan-03-26 07:20AM	Ironwood backs FY25 revenue view $290M-$310M, consensus $306.97M (TipRanks)
07:20AM	Ironwood sees FY26 revenue $450M-$475M, consensus $319.47M (TipRanks)
Jan-02-26 12:21PM	Ironwood Pharmaceuticals Stock Soars as Drug-Price Cut Boosts Prospects for 2026 (Barrons.com) +26.71%
07:05AM	Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance (Business Wire)
Dec-10-25 11:30AM	Why Is Ironwood (IRWD) Up 24.9% Since Last Earnings Report? (Zacks)
Nov-28-25 10:11AM	Ironwood (IRWD) Skyrockets 23% as Govt Price for Linzess Falls Within Expectations (Insider Monkey) -9.33%
Nov-27-25 11:58AM	IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick? (Zacks)
Nov-21-25 10:30AM	Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3? (Zacks)
Nov-13-25 10:36AM	IRWD Rises 110% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks) +8.36%
Nov-11-25 09:56AM	IRWD Beats on Q3 Earnings & Revenues, Raises 2025 View, Stock Soars (Zacks) +14.23%
Nov-10-25 08:25AM	Ironwood Pharmaceuticals (IRWD) Q3 Earnings and Revenues Surpass Estimates (Zacks) +31.77%
07:21AM	Ironwood: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance (Business Wire)
Nov-06-25 07:35AM	Former blockbuster Linzess grows label with paediatric IBS-C approval (Pharmaceutical Technology)
Nov-05-25 05:35PM	Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +10.16%
Oct-20-25 09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue? (Zacks) +7.69%
Oct-16-25 07:56AM	BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock? (Zacks)
Oct-15-25 09:17AM	Teladoc Health Expands Clarity Platform With Workplace Safety Tool (Zacks) +8.78%
06:19AM	Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics (Zacks)
Oct-14-25 10:57AM	5 Small Drug Stocks to Buy as the Industry Shows Some Recovery (Zacks)
09:50AM	Why Ironwood Pharmaceuticals (IRWD) is a Top Momentum Stock for the Long-Term (Zacks)
Sep-22-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Aug-21-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks) +7.27%
Aug-08-25 10:36AM	IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates (Zacks)
Aug-07-25 08:25AM	Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates (Zacks) +9.32%
07:26AM	Ironwood: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance (Business Wire)
Jun-06-25 11:31AM	Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report? (Zacks) +6.58%
May-08-25 09:55AM	IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates (Zacks) -11.63%
May-07-25 08:20AM	Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -14.55%
07:26AM	Ironwood: Q1 Earnings Snapshot (Associated Press Finance)
07:05AM	Ironwood Pharmaceuticals Reports First Quarter 2025 Results (Business Wire)
May-06-25 10:00AM	Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
May-05-25 07:15AM	Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-03-25 10:24PM	The 1-Minute Market Report May 4, 2025 (Seeking Alpha)
May-01-25 10:01AM	Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-30-25 04:25PM	Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference (Business Wire)
Apr-28-25 10:25AM	The 1-Minute Market Report April 27, 2025 (Seeking Alpha) +9.23%
Apr-25-25 07:05AM	Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance (Business Wire)
Apr-22-25 04:05PM	Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support (Business Wire) +7.66%
Apr-16-25 01:07PM	Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News (Zacks)
Apr-15-25 09:18AM	Ironwood Shares Tank on Regulatory Update for Apraglutide (Zacks) +11.47%
07:12AM	Ironwoods shares sink as FDA demands new trial for lead drug (Pharmaceutical Technology)
Apr-14-25 07:00AM	Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide (Business Wire) -31.48%
Apr-13-25 10:44AM	The 1-Minute Market Report April 13, 2025 (Seeking Alpha)
Apr-10-25 10:49AM	Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth (Seeking Alpha)
09:25AM	Why Ironwood Pharmaceuticals Inc. (IRWD) Went Down On Thursday? (Insider Monkey)
Apr-01-25 10:28AM	Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar? (Zacks)
Mar-31-25 08:05AM	The 1-Minute Market Report March 30, 2025 (Seeking Alpha)
Mar-27-25 04:05PM	Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing (Business Wire)
Mar-25-25 11:08AM	Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? (Zacks)
Mar-02-25 12:24PM	Is Ironwood Pharmaceuticals, Inc. (IRWD) the Best Small Cap Pharma Stock to Buy Now? (Insider Monkey)
Feb-28-25 02:14AM	Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Call Highlights: Strong Prescription ... (GuruFocus.com)
Feb-27-25 11:20PM	Q4 2024 Ironwood Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -5.26%
08:15AM	Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Miss Estimates (Zacks)
07:20AM	Ironwood: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance (Business Wire)
Feb-26-25 08:13AM	Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-20-25 04:00PM	Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call (Business Wire)
Feb-05-25 06:28PM	Millrose Properties Set to Join S&P SmallCap 600 (PR Newswire) -8.06%
Jan-29-25 04:05PM	Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future (Business Wire) -38.17%
Jan-18-25 08:20AM	Ozempic, Xtandi among next 15 drugs selected for U.S. price talks (TipRanks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shetzline Michael	Former Officer	Sep 24 '26	Proposed Sale	4.53	83,306	377,376		Sep 23 04:08 PM
Silver Ronald	PFO & PAO	Jul 07 '26	Sale	4.52	127,890	578,063	313,680	Jul 09 04:32 PM
RONALD SILVER	Officer	Jul 07 '26	Proposed Sale	4.38	127,890	560,158		Jul 07 04:43 PM
McHugh Julie	Director	Jun 16 '26	Sale	3.73	21,571	80,460	250,749	Jun 17 04:41 PM
JULIE MCHUGH	Director	Jun 16 '26	Proposed Sale	3.69	21,571	79,597		Jun 16 04:37 PM
DENNER ALEXANDER J	Director	Mar 17 '26	Sale	3.05	6,730,800	20,530,448	9,188,635	Mar 17 08:34 PM
John Minardo	Chief Legal Officer	Feb 24 '26	Sale	3.66	19,053	69,734	363,886	Feb 25 04:05 PM
John Minardo	Chief Legal Officer	Feb 23 '26	Sale	3.81	17,439	66,443	382,939	Feb 25 04:05 PM
Shetzline Michael	SVP, CMO, Head-Res&Drug	Feb 23 '26	Sale	3.81	15,570	59,322	538,437	Feb 25 04:05 PM
Gaskins Tammi L	Chief Commercial Officer	Feb 24 '26	Sale	3.66	11,239	41,135	213,738	Feb 25 04:05 PM
Gaskins Tammi L	Chief Commercial Officer	Feb 23 '26	Sale	3.81	10,287	39,193	224,977	Feb 25 04:05 PM
MCCOURT Thomas A	Chief Executive Officer	Feb 24 '26	Sale	3.66	103,526	378,905	1,489,002	Feb 25 04:05 PM
MCCOURT Thomas A	Chief Executive Officer	Feb 23 '26	Sale	3.81	94,757	361,024	1,592,528	Feb 25 04:05 PM
Martini Gregory S.	Chief Financial Officer	Feb 24 '26	Sale	3.66	11,457	41,933	160,601	Feb 25 04:05 PM
Martini Gregory S.	Chief Financial Officer	Feb 23 '26	Sale	3.81	10,487	39,955	172,058	Feb 25 04:05 PM
Silver Ronald	Principal Accounting Officer	Feb 24 '26	Sale	3.66	12,621	46,193	252,636	Feb 25 04:05 PM
Silver Ronald	Principal Accounting Officer	Feb 23 '26	Sale	3.81	11,552	44,013	265,257	Feb 25 04:05 PM
Gaskins Tammi L	Officer	Feb 23 '26	Proposed Sale	4.61	19,775	91,163		Feb 20 04:46 PM
Martini Gregory S.	Officer	Feb 23 '26	Proposed Sale	4.61	20,163	92,951		Feb 20 04:45 PM
Shetzline Michael	Officer	Feb 23 '26	Proposed Sale	4.61	29,937	138,010		Feb 20 04:44 PM
John Minardo	Officer	Feb 23 '26	Proposed Sale	4.61	33,528	154,564		Feb 20 04:42 PM
MCCOURT Thomas A	Officer	Feb 23 '26	Proposed Sale	4.61	182,185	839,873		Feb 20 04:41 PM
Silver Ronald	Principal Accounting Officer	Jan 05 '26	Sale	4.60	35,416	162,914	276,809	Jan 07 04:05 PM
RONALD SILVER	Officer	Jan 05 '26	Proposed Sale	4.27	35,416	151,226		Jan 05 04:41 PM
Gaskins Tammi L	Chief Commercial Officer	Nov 17 '25	Sale	3.32	6,016	19,973	235,264	Nov 19 04:05 PM
Gaskins Tammi L	Officer	Nov 17 '25	Proposed Sale	3.37	6,324	21,312		Nov 14 04:05 PM

Ironwood Pharmaceuticals, Inc. is a biotechnology company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

CEO & DirectorMr. Thomas A. McCourt

Senior VPMr. Ronald Silver

M.S.Dr. Rosario Lobrutto M.B.A.

Senior VPMr. John Minardo

Chief Strategy OfficerMr. Jeff Ruberti

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IRWD

Ironwood Pharmaceuticals Inc

Upgrade your Finviz experience